Melissa Karrh
Psychiatry · Birmingham, ALNPI 1720402936
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $33,330 of the $50,625 with a category attached, or 65.8%. AbbVie accounts for 62.0% of it on its own, with 26 other manufacturers making up the rest. 2025 is the largest year on record at $17,944, 4.0 times the $4,464 reported in 2021. Among psychiatry clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 530 payments — averaging $95.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$31K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$9K
- Supernus Pharmaceuticals, Inc.$4K
- Vanda Pharmaceuticals Inc.$1K
- Teva Pharmaceuticals USA, Inc.$726
- Axsome Therapeutics, Inc.$678
- plus $4K from 21 others
What the payments were for
- Consulting fees$3,1886%
- Speaking & faculty fees$33,33066%
- Travel & lodging$4,0568%
- Food & beverage$9,92520%
- Education$1260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 134 | $31,405 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 80 | $8,660 |
| Supernus Pharmaceuticals, Inc. | 42 | $4,428 |
| Vanda Pharmaceuticals Inc. | 44 | $1,014 |
| Teva Pharmaceuticals USA, Inc. | 47 | $726 |
| Axsome Therapeutics, Inc. | 25 | $678 |
| Alkermes, Inc. | 17 | $648 |
| Takeda Pharmaceuticals U.S.A., Inc. | 29 | $581 |
| Otsuka America Pharmaceutical, Inc. | 20 | $492 |
| Lundbeck LLC | 21 | $392 |
| Johnson & Johnson | 8 | $319 |
| Corium, LLC | 11 | $249 |
| Tris Pharma Inc | 12 | $221 |
| Ironshore Pharmaceuticals Inc. | 6 | $208 |
| Bausch Health US, LLC | 8 | $171 |
| Neos Therapeutics, LP | 7 | $115 |
| Almatica Pharma LLC | 3 | $52 |
| Eisai Inc. | 3 | $43 |
| E.r. Squibb & Sons, L.L.C. | 2 | $40 |
| Vertical Pharmaceuticals, LLC | 2 | $34 |
| Collegium Pharmaceutical, Inc. | 2 | $32 |
| Neuronetics, Inc. | 1 | $27 |
| Neurocrine Biosciences, Inc. | 1 | $25 |
| Adlon Therapeutics L.p. | 2 | $24 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Jazz Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$50,625 in reported general payments places this provider in the 95th percentile of 400 psychiatry providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 81 | $149,142 |
| AustedoDeutetrabenazine | 13 | $71,847 |
| Lurasidone Hcl | 43 | $24,908 |
| Aripiprazole | 150 | $12,790 |
| Vilazodone Hcl | 89 | $11,187 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 178 | $10,307 |
| VyvanseLisdexamfetamine Dimesylate | 24 | $8,803 |
| LexaproEscitalopram Oxalate | 12 | $7,243 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 179 | $5,927 |
| Duloxetine Hcl | 111 | $5,066 |
| Bupropion XlBupropion Hcl | 99 | $3,067 |
| Trazodone Hcl | 116 | $2,688 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 66 | $2,593 |
| Mirtazapine | 147 | $1,874 |
| Quetiapine Fumarate | 111 | $1,681 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Lexapro | $31,405 | $156,38593 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $726 | $71,84713 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $581 | $8,80324 claims |
| Almatica Pharma LLCSertraline Hcl | $52 | $43822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 400 psychiatry providers in Alabama.
Other psychiatry in Birmingham
- Armand SchachterBirmingham$758K
- Stephen HughesBirmingham$683K
- Leesha Ellis CoxBirmingham$653K
- Godehard OepenBirmingham$516K
- Richard SheltonBirmingham$79K
- Matthew MacalusoBirmingham$49K
- Santosh PillaiBirmingham$28K
- Jennifer HadleyBirmingham$27K
- Kerry ClearyBirmingham$12K
- Praveen JettyBirmingham$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.